Placebo Effect Hinders Quality Of Chronic Pain Treatment Trials – FDA, CMS
This article was originally published in The Gray Sheet
Executive Summary
Chronic pain therapy manufacturers must meet challenges presented by the placebo effect when designing clinical trials, according to FDA and CMS
You may also be interested in...
Medtronic’s Restore, W.L. Gore’s Tag Receive New Tech Add-On Payment
Medtronic's argument that the Restore rechargeable implantable neurostimulator represents a substantial clinical improvement over existing devices convinced CMS to award the device new technology add-on payment for fiscal year 2007
Acupuncture Noncoverage Decisions Maintained By CMS Due To Poor Data
Further evidence on the effect of sham versus real acupuncture for relief of osteoarthritis pain headlines a long list of research issues that need to be addressed before CMS reverses its noncoverage policy for the alternative therapy
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.